THE US Food and Drug
Administration (FDA) has released
a trials snapshot of TAGRISSO, a
drug used to treat patients with
advanced non-small cell lung
cancer (NSCL).
Clinical trials for the drug were
conducted globally on a total of 411
patients across 10 countries with
NSCL, all with the T790M mutation
whose condition worsened
following treatment with EGFRblocking
medication.
Taken as a tablet by mouth once
a day, TAGRISSO was found to have
a “significant effect on reducing
tumour size on over half of patients
who were treated”.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jan 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.